Table 3.
Proportions of deaths between CPAP and HFNO groups by sex, comorbidity, and therapy subgroups.
| DeathsCPAP (n = 108) |
DeathsHFNT (n = 108) |
p | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Sex | |||||
| Female | 42 | 66.66 | 48 | 62.50 | 0.8488 |
| Male | 66 | 78.78 | 60 | 66.66 | 0.1836 |
| Cardiovascular comorbidities (present) | 82 | 73.17 | 89 | 64.04 | 0.2634 |
| Metabolic comorbidities (present) | 64 | 78.12 | 62 | 61.29 | 0.0624 |
| Neurological comorbidities (present) | 39 | 79.48 | 32 | 62.50 | 0.1877 |
| Renal and hepatic comorbidities (present) | 40 | 75.00 | 32 | 68.75 | 0.7462 |
| Oncological comorbidities (present) | 9 | 66.66 | 18 | 88.88 | 0.3813 |
| Pulmonary comorbidities (present) | 8 | 100 | 3 | 100 | – |
| Tocilizumab therapy (present) | 28 | 57.14 | 30 | 73.33 | 0.3078 |
| Remdesivir therapy (present) | 54 | 74.07 | 76 | 73.68 | 0.8787 |
| Corticosteroid therapy (present) | 90 | 75.55 | 94 | 65.95 | 0.2050 |
CPAP, continuous positive airway pressure; HFNO, high-flow nasal oxygen therapy.